Lobbying Spend
—
Filings
3
Firms Hired
1
Active Period
2024–2025
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Access to Prescription Digital Therapeutics Act of 2023
2024 · fourth_quarter · Firm: BLUEBIRD STRATEGIES
Access to Prescription Digital Therapeutics Act of 2023 (H.R. 1458/S. 723) American Medical Innovation and Investment Act (H.R. 8816)
Client expense: — · Firm income: —
Matched citations: H.R. 1458
American Medical Innovation and Investment Act of 2024
2024 · fourth_quarter · Firm: BLUEBIRD STRATEGIES
Access to Prescription Digital Therapeutics Act of 2023 (H.R. 1458/S. 723) American Medical Innovation and Investment Act (H.R. 8816)
Client expense: — · Firm income: —
Matched citations: H.R. 8816
Access to Prescription Digital Therapeutics Act of 2023
2024 · fourth_quarter · Firm: BLUEBIRD STRATEGIES
Access to Prescription Digital Therapeutics Act of 2023 (H.R. 1458/S. 723) American Medical Innovation and Investment Act (H.R. 8816)
Client expense: — · Firm income: —
Matched citations: S. 723
Access to Prescription Digital Therapeutics Act of 2023
2024 · fourth_quarter · Firm: BLUEBIRD STRATEGIES
American Medical Innovation and Investment Act (H.R. 8816) Section 6 requiring CMS to issue guidance on coverage/reimbursement of prescription digital therapeutics under Medicare Part B and asa supplemental benefit to an individual enrolled under a Medicare Advantage plan. Legislative efforts to require CMS to issue guidance to state Medicaid Directors regarding coverage of PDTs underMedicaid and the State Childrens Health Insurance Program. Access to Prescription Digital Therapeutics Act (H.R. 1458/S. 723) to establish Medicare/Medicaid benefit categories for PDTs. Matters related to the adoption of and reimbursement for digital health technologies.
Client expense: — · Firm income: —
Matched citations: H.R. 1458
Access to Prescription Digital Therapeutics Act of 2023
2024 · fourth_quarter · Firm: BLUEBIRD STRATEGIES
American Medical Innovation and Investment Act (H.R. 8816) Section 6 requiring CMS to issue guidance on coverage/reimbursement of prescription digital therapeutics under Medicare Part B and asa supplemental benefit to an individual enrolled under a Medicare Advantage plan. Legislative efforts to require CMS to issue guidance to state Medicaid Directors regarding coverage of PDTs underMedicaid and the State Childrens Health Insurance Program. Access to Prescription Digital Therapeutics Act (H.R. 1458/S. 723) to establish Medicare/Medicaid benefit categories for PDTs. Matters related to the adoption of and reimbursement for digital health technologies.
Client expense: — · Firm income: —
Matched citations: H.R. 1458
American Medical Innovation and Investment Act of 2024
2024 · fourth_quarter · Firm: BLUEBIRD STRATEGIES
American Medical Innovation and Investment Act (H.R. 8816) Section 6 requiring CMS to issue guidance on coverage/reimbursement of prescription digital therapeutics under Medicare Part B and asa supplemental benefit to an individual enrolled under a Medicare Advantage plan. Legislative efforts to require CMS to issue guidance to state Medicaid Directors regarding coverage of PDTs underMedicaid and the State Childrens Health Insurance Program. Access to Prescription Digital Therapeutics Act (H.R. 1458/S. 723) to establish Medicare/Medicaid benefit categories for PDTs. Matters related to the adoption of and reimbursement for digital health technologies.
Client expense: — · Firm income: —
Matched citations: H.R. 8816
American Medical Innovation and Investment Act of 2024
2024 · fourth_quarter · Firm: BLUEBIRD STRATEGIES
American Medical Innovation and Investment Act (H.R. 8816) Section 6 requiring CMS to issue guidance on coverage/reimbursement of prescription digital therapeutics under Medicare Part B and asa supplemental benefit to an individual enrolled under a Medicare Advantage plan. Legislative efforts to require CMS to issue guidance to state Medicaid Directors regarding coverage of PDTs underMedicaid and the State Childrens Health Insurance Program. Access to Prescription Digital Therapeutics Act (H.R. 1458/S. 723) to establish Medicare/Medicaid benefit categories for PDTs. Matters related to the adoption of and reimbursement for digital health technologies.
Client expense: — · Firm income: —
Matched citations: H.R. 8816
Access to Prescription Digital Therapeutics Act of 2023
2024 · fourth_quarter · Firm: BLUEBIRD STRATEGIES
American Medical Innovation and Investment Act (H.R. 8816) Section 6 requiring CMS to issue guidance on coverage/reimbursement of prescription digital therapeutics under Medicare Part B and asa supplemental benefit to an individual enrolled under a Medicare Advantage plan. Legislative efforts to require CMS to issue guidance to state Medicaid Directors regarding coverage of PDTs underMedicaid and the State Childrens Health Insurance Program. Access to Prescription Digital Therapeutics Act (H.R. 1458/S. 723) to establish Medicare/Medicaid benefit categories for PDTs. Matters related to the adoption of and reimbursement for digital health technologies.
Client expense: — · Firm income: —
Matched citations: S. 723
Access to Prescription Digital Therapeutics Act of 2023
2024 · fourth_quarter · Firm: BLUEBIRD STRATEGIES
American Medical Innovation and Investment Act (H.R. 8816) Section 6 requiring CMS to issue guidance on coverage/reimbursement of prescription digital therapeutics under Medicare Part B and asa supplemental benefit to an individual enrolled under a Medicare Advantage plan. Legislative efforts to require CMS to issue guidance to state Medicaid Directors regarding coverage of PDTs underMedicaid and the State Childrens Health Insurance Program. Access to Prescription Digital Therapeutics Act (H.R. 1458/S. 723) to establish Medicare/Medicaid benefit categories for PDTs. Matters related to the adoption of and reimbursement for digital health technologies.
Client expense: — · Firm income: —
Matched citations: S. 723
Source: Senate LDA